VRDN Stock Analysis: Viridian Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.615m USD | 12M Return: 20.3% | US92790C1045 | Charts, Fundamentals & Technical Analysis

Monoclonal Antibodies, Thyroid Therapies, FcRn Inhibitors, Autoimmune Treatments
Total Rating 27
Safety 35
Buy Signal -0.80
Biotechnology
Industry Rotation: +10.5
Market Cap: 2.61B
Avg Turnover: 33.9M
Risk 3d forecast
Volatility61.2%
VaR 5th Pctl9.69%
VaR vs Median-3.92%
Reward TTM
Sharpe Ratio0.57
Rel. Str. IBD49.2
Rel. Str. Peer Group20.8
Character TTM
Beta0.743
Beta Downside0.238
Hurst Exponent0.546
Drawdowns 3y
Max DD60.63%
CAGR/Max DD0.11
CAGR/Mean DD0.24
EPS (Earnings per Share) EPS (Earnings per Share) of VRDN over the last years for every Quarter: "2021-09": -1.25, "2021-12": -1.32, "2022-03": -0.98, "2022-06": -1.06, "2022-09": -0.86, "2022-12": -1.13, "2023-03": -1.61, "2023-06": -1.27, "2023-09": -1.09, "2023-12": -1.35, "2024-03": -0.79, "2024-06": -1.02, "2024-09": -1.15, "2024-12": -0.81, "2025-03": -0.87, "2025-06": -1, "2025-09": -0.34, "2025-12": -1.08, "2026-03": -0.9, "2026-06": -1.05,
Last SUE: -0.37
Qual. Beats: 0
Revenue Revenue of VRDN over the last years for every Quarter: 2021-09: 0.208, 2021-12: 0.214, 2022-03: 0.216, 2022-06: 0.256, 2022-09: 1.195, 2022-12: 0.105, 2023-03: 0.098, 2023-06: 0.072, 2023-09: 0.072, 2023-12: 0.072, 2024-03: 0.072, 2024-06: 0.072, 2024-09: 0.086, 2024-12: 0.072, 2025-03: 0.072, 2025-06: 0.075, 2025-09: 70.57, 2025-12: 0.132, 2026-03: 0.141, 2026-06: 0.284,
Rev. CAGR: 1030.74%
Rev. Trend: 81.5%
Last SUE: 0.01
Qual. Beats: 0

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation
Altman Z'' In Financial Distress Zone
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +3.3% 30
Feb -10.0% 22
Mar -1.7% 11
Apr +4.0% 26
May -0.7% 7
Jun -1.1% 8
Jul +7.2% 30
Aug -5.1% 26
Sep -2.8% 11
Oct -1.8% 13
Nov +15.7% 33
Dec -3.5% 11

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: VRDN Viridian Therapeutics

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a U.S.-based clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and rare diseases. The company was originally incorporated in 2010 as Miragen Therapeutics, Inc. and rebranded under its current name in January 2021.

Its pipeline centers on thyroid eye disease (TED), led by two differentiated IGF-1R antibodies: Veligrotrug, an intravenously administered humanized monoclonal antibody, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R therapy. Viridian is also advancing an anti-TSHR candidate for Graves disease and TED, along with engineered neonatal Fc receptor (FcRn) inhibitors-VRDN-006, a selective Fc fragment, and VRDN-008, a half-life-extended bispecific FcRn inhibitor designed to prolong IgG suppression.

As a small-cap biotechnology company, Viridian operates a typical clinical-stage biotech business model, prioritizing R&D investment and pipeline advancement over near-term commercial revenue generation. The company is listed on NASDAQ and is classified within the Health Care sectors Biotechnology sub-industry.

Headlines to Watch Out For
  • Veligrotrug approval timing drives near-term stock catalyst
  • Tepezza competition limits TED market share opportunity
  • Cash burn and dilution risk fund FcRn pipeline advancement
Piotroski VR-10 (Strict) 0.0
Net Income: -387.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.31 > 0.02 and ΔFCF/TA 24.04 > 1.0
NWC/Revenue: 1.43k% < 20% (prev 173k%; Δ -171k% < -1%)
CFO/TA -0.30 > 3% & CFO -333.3m > Net Income -387.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 16.95 > 1.5 & < 3
Outstanding Shares: last quarter (107.9m) vs 12m ago 32.22% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 8.47% > 50% (prev 0.05%; Δ 8.42% > 0%)
Interest Coverage Ratio: -19.43 > 6 (EBIT TTM -368.0m / Interest Expense TTM 18.9m)
Altman Z'' 0.07
A: 0.93 (Total Current Assets 1.08b - Total Current Liabilities 63.8m) / Total Assets 1.10b
B: -1.43 (Retained Earnings -1.57b / Total Assets 1.10b)
C: -0.44 (EBIT TTM -368.0m / Avg Total Assets 839.8m)
D: 1.52 (Book Value of Equity 662.1m / Total Liabilities 435.1m)
Altman-Z'' = 0.07 = B
Beneish M 1.00
DSRI: 0.10 (Receivables 75.0m/70.0m, Revenue 71.1m/305k)
GMI: 1.00 (fallback, negative margins)
AQI: 11.66 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 233.2 (Revenue 71.1m / 305k)
TATA: -0.05 (NI -387.0m - CFO -333.3m) / TA 1.10b)
Beneish M = 169.0 (Cap -4..+1) = D
What is the price of VRDN shares?

As of September 02, 2026, the stock is trading at USD 23.03 with a total of 997,883 shares traded. Over the past week, the price has changed by -4.76%, over one month by +19.26%, over three months by +35.79% and over the past year by +20.32%.

Current recommended Stop Loss: 22.00 (which is 4.5% or 1.2 ATR below the current price).

Is VRDN a buy, sell or hold?

Viridian Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy VRDN.

  • StrongBuy: 9
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the VRDN price?
Analysts Target Price 36.6 59.1%
Viridian Therapeutics (VRDN) - Fundamental Data Overview as of 30 August 2026
Market Cap USD = 2.61b (2.61b USD * 1.0 USD.USD)
P/E Forward = 1.0072
P/S = 36.7622
P/B = 4.7982
Revenue TTM = 71.1m USD
EBIT TTM = -368.0m USD
EBITDA TTM = -368.0m USD
Long Term Debt = 242.2m USD (from longTermDebt, last quarter)
Short Term Debt = 722k USD (from shortTermDebt, last quarter)
Debt = 243.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 722k
Net Debt = -661.4m USD (calculated: Debt 243.6m - CCE 905.0m)
Enterprise Value = 1.95b USD (2.61b + Debt 243.6m - CCE 905.0m)
Interest Coverage Ratio = -19.43 (Ebit TTM -368.0m / Interest Expense TTM 18.9m)
EV/FCF = -5.82x (Enterprise Value 1.95b / FCF TTM -335.6m)
FCF Yield = -17.18% (FCF TTM -335.6m / Enterprise Value 1.95b)
 FCF Margin = -471.8% (FCF TTM -335.6m / Revenue TTM 71.1m)
 Net Margin = -544.1% (Net Income TTM -387.0m / Revenue TTM 71.1m)
 Gross Margin = unknown ((Revenue TTM 71.1m - Cost of Revenue TTM 1.16m) / Revenue TTM)
 Tobins Q-Ratio = 1.78 (Enterprise Value 1.95b / Total Assets 1.10b)
Interest Expense / Debt = 7.77% (Interest Expense 18.9m / Debt 243.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -290.7m (EBIT -368.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.93 (Total Current Assets 1.08b / Total Current Liabilities 72.4m)
Debt / Equity = 0.37 (Debt 243.6m / totalStockholderEquity, last quarter 662.1m)
 Debt / EBITDA = 1.80 (negative EBITDA) (Net Debt -661.4m / EBITDA -368.0m)
 Debt / FCF = 1.97 (negative FCF - burning cash) (Net Debt -661.4m / FCF TTM -335.6m)
 Total Stockholder Equity = 630.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.08% (Net Income -387.0m / Total Assets 1.10b)
RoE = -61.35% (Net Income TTM -387.0m / Total Stockholder Equity 630.8m)
RoCE = -42.16% (EBIT -368.0m / Capital Employed (Equity 630.8m + L.T.Debt 242.2m))
 RoIC = -28.21% (negative operating profit) (NOPAT -290.7m / Invested Capital 1.03b)
 WACC = 8.39% (E(2.61b)/V(2.86b) * Re(8.60%) + D(243.6m)/V(2.86b) * Rd(7.77%) * (1-Tc(0.21)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.72 | Cagr: 28.75%
 [DCF] Fair Price = unknown (Cash Flow -335.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: 81.50 | Revenue CAGR: 1.03k% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.99 | Chg30d=-6.69% | Revisions=-36% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.95 | Chg30d=-3.93% | Revisions=-55% | GrowthEPS=-18.9% | GrowthRev=-60.6%
EPS next Year (2027-12-31): EPS=-2.77 | Chg30d=-5.34% | Revisions=-50% | GrowthEPS=+29.8% | GrowthRev=+729.2%
[Analyst] Revisions Ratio: -58% (up=4, down=19)